Top 10 at 10: Positive phase 1 trials and a $21m US govt contract

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data.

It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.

The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has started trading.

 

WINNERS

Stocks highlighted in yellow have made market-moving announcements (click headings to sort).

WordPress Table

Medibio (ASX:MEB) reports “promising initial results” from a Phase 1 trial looking at relationship between mental illness and sleep.

The clinical trial aimed to detect the likelihood of a current major depressive episode in individuals referred to sleep clinics for PSG assessment.

Phase 2 enrolment set to complete shortly.

Micro-X (ASX:MX1) has been awarded an extension on its development contract with the U.S. Department of Homeland Security to build and test self-screening checkpoint modules in an operating airport.

The total contract extension is worth up to $21m (USD$14m) over 40 months.

Global Health (ASX:GLH) says it returned to positive cashflow in Q4 FY23.

 

LOSERS

Stocks highlighted in yellow have made market-moving announcements (click headings to sort).

WordPress Table